Omission of Postoperative Radiation in HPV-Associated Oropharyngeal Cancer Using ctHPVDNA Surveillance (OPERATION)

Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorMedical University of South Carolina

About this trial

This single-arm Phase II trial evaluates whether omission of postoperative radiotherapy is feasible and oncologically safe in select patients with HPV-associated oropharyngeal squamous cell carcinoma (HPV-OPSCC). Eligible patients undergo transoral robotic surgery (TORS) and are observed without adjuvant radiation if they demonstrate low or intermediate pathological risk features and have negative circulating tumor HPV DNA (ctHPVDNA) two weeks post-operatively. Patients are followed with standard clinical surveillance combined with serial ctHPVDNA testing (NavDx®) to facilitate early detection of recurrence and prompt salvage therapy as needed.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Provision of signed and dated informed consent form.

Stated willingness to comply with all study procedures and availability for the duration of the study.

Male or female, ≥ 18 years of age (no upper age limit).

Biopsy proven squamous cell carcinoma.

Disqualifiers

Prior history of surgery to the head and neck that in the opinion of the investigators would modify prognostic significance of pathology results.

Prior history of radiation therapy to the head and neck, with the exception of skin cancer treated with a small (≤ 9cm3) field with 6 - 9 MeV electron beam or 50 - 250 kVp photon beam.

Basal cell carcinoma of the skin

Squamous cell carcinoma of the skin, stage 1-2

Trial design

Design model

Single group

Treatments tested in this trial

  • Active Surveillance With ctHPVDNA (NavDx®)

    Other intervention

    Active surveillance without postoperative radiation using routine clinical follow-up and serial ctHPVDNA testing to detect recurrence.

Treatment groups

36 Participants
are divided into 1 treatment group
Group A: Active Surveillance With ctHPVDNA After SurgeryExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Local-Regional Control

Proportion of participants without local or regional recurrence above the clavicles at 2 years following definitive surgery, including participants who recur but are successfully salvaged with radiation or chemotherapy during the 2-year postoperative period.

Time frame
2 years post-surgery

Secondary outcomes

1

Progression-Free Survival (PFS)

Time from surgery to disease progression or death from any cause.

Time frame
2 years after definitive surgery
2

Distant Metastasis-Free Survival (DMFS)

Time from surgery to development of distant metastatic disease or death.

Time frame
2 years after definitive surgery
3

Overall Survival (OS)

Time from surgery to death from any cause.

Time frame
2 years after definitive surgery
4

Swallowing Function (Functional Oral Intake Scale - FOIS)

Change in swallowing function measured using the Functional Oral Intake Scale (FOIS).

Time frame
Baseline through 24 months post-surgery

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.